Arlo at Citi’s 2026 Global TMT Conference: services drive growth

Arlo said services now account for roughly 60% of revenue and are growing about 20% year over year, while blended gross margin has expanded to 50% from 30% and operating margin reached nearly 20% in the latest quarter. Management targets more than 10 million subscribers, $700 million in ARR and operating margin above 25%, supported by partnerships expected to generate 60% of incremental growth. Arlo Secure 7's AI threat-assessment launch, planned pricing increases next year, and the Aloe Care Health acquisition provide additional monetization and long-term growth opportunities, although execution in a competitive home-security market remains a key risk.

Analysis

ARLO’s valuation now hinges less on subscriber growth than on proof that partner-led acquisition can scale without surrendering economics. The critical diligence item is whether channel partners fund hardware, marketing, installation/support and customer ownership; a headline subscriber ramp with lower net revenue retention or elevated support costs would dilute the apparent software multiple. Secure 7 is a near-term engagement catalyst, but AI functionality alone is unlikely to establish a durable moat against AMZN/Ring and GOOG/Nest unless it demonstrably lowers false-negative rates, cloud-compute cost per monitored event, or churn.

The market is likely underestimating the execution gap between partner announcements and material ARR. CMCSA integration is not expected to contribute meaningfully until 2H27, while the healthcare adjacency carries a longer regulatory, reimbursement and distribution cycle; neither should support aggressive 2026 estimate revisions absent disclosed bookings or minimum commitments. Conversely, a privacy-first architecture could matter disproportionately in provider, insurer and aging-in-place channels, where AMZN’s advertising/data ecosystem may be a procurement handicap rather than an advantage.

Near term, ARLO’s sharp momentum makes the setup vulnerable to a "show me" response around Secure 7 and next-quarter ARPU/net-add disclosure. Over 6-18 months, the upside case requires sustained service growth, margin expansion despite hardware promotions, and partner mix that does not increase CAC above the company’s stated economic guardrails. Falsify the constructive thesis if service growth decelerates materially, ARPU stalls after the feature rollout, blended gross margin retreats, or partner launch dates slip; those outcomes would expose a premium multiple without a commensurate recurring-revenue re-rating.

Key Decisions for Investors

• Do not chase ARLO after the recent momentum; establish a 1-3 month watch position only after Secure 7 launch data confirms higher-tier attachment or reduced churn. Add on evidence of service growth holding near management’s target with stable CAC; target a 20-30% upside from multiple expansion, with a 10-12% stop if post-launch KPIs disappoint.
• Use a 6-12 month ARLO long / ADT short pair only if ADT discloses meaningful DIY adoption through the partnership. ARLO should retain more operating leverage from software monetization, while ADT bears channel-transition and legacy monitored-security mix risk; exit if ARLO’s partner economics show lower gross margin or ADT’s DIY penetration exceeds expectations.
• Treat CMCSA as an event-driven watch item rather than a current beneficiary. Reassess ahead of the planned integration launch; a bundled security offer that reduces broadband churn would be strategically positive, but the financial contribution is immaterial until subscriber conversion, revenue share and hardware subsidy terms are disclosed.
• Avoid assigning healthcare-adjacency value to ARLO until it provides independently verifiable partner contracts, reimbursement pathway details, and 2027 revenue guidance. The acquisition can create optionality, but privacy compliance and product claims do not by themselves validate demand or unit economics.